abstract |
The present invention relates to a compound, which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-( ((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4 -methylphenyl) propionic acid, or a pharmaceutically acceptable salt thereof, especially its meglumine salt, a pharmaceutical composition comprising the compound and its use as an NRF2 activator. |